Chronic Hepatitis B Clinical Trial
Official title:
Treatment Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in naïve Chronic Hepatitis B : a Real Life Multicenter Cohort Study in Korea
NCT number | NCT02533544 |
Other study ID # | IN-US-174-1805 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | October 2015 |
Est. completion date | October 2018 |
Verified date | January 2019 |
Source | The Catholic University of Korea |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This is an open-label, single arm cohort study to see efficacy and safety of tenofovir disoproxil fumarate (TDF) in naïve chronic hepatitis B, retrospectively and prospectively both.
Status | Completed |
Enrollment | 572 |
Est. completion date | October 2018 |
Est. primary completion date | October 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years and older |
Eligibility |
Inclusion Criteria: 1. Must have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures. 2. Adult male and non-pregnant, non-lactating female subjects, 19 years of age and older, based on the date of the screening visit. A negative serum pregnancy test at Screening is required for female subjects of childbearing potential (unless surgically sterile or greater than 2 years post-menopausal). 3. Documented evidence of chronic HBV infection (e.g. HBsAg positive for more than 6 months) 4. Chronic hepatitis B with the following: - HBeAg-positive and HBeAb negative at Screening - Screening HBV DNA = 1x 105 copies/mL - Screening serum ALT level = ×ULN(80 IU/L) and = 10 ×ULN (by center laboratory range) OR - HBeAg-negative and HBeAb positive at Screening - Screening HBV DNA = 1x 104 copies/mL - Screening serum ALT level = ×ULN(80 IU/L) and = 10 ×ULN (by center laboratory range) OR - Cirrhosis at Screening - Screening HBV DNA = 1x 104 copies/mL in HBeAg negative or - Screening HBV DNA = 1x 105 copies/mL in HBeAg positive - Screening serum ALT level = ×ULN and = 10 ×ULN (by center laboratory range) 5. A patient who treating with TDF as a treatment-naïve for Hepatitis B. Treatment naïve subjects defined as no history of antiviral therapy or < 12 weeks of oral antiviral treatment with any nucleoside or nucleotide analogue, including lamivudine or adefovir, clevudine, telbivudine, entecavir 6. Decompensated liver cirrhosis defined based on a Child-Turcotte-Pugh (CTP) score = 7 (Child B and C) or presence with at least one episode of ascites, jaundice, hepatic encephalopathy or variceal bleeding 7. Any previous treatment with interferon (pegylated or non-pegylated) must have ended at least 6 months prior to the baseline visit 8. Must be willing and able to comply with all study requirements. Exclusion Criteria: Subjects who meet any of the following exclusion criteria are not to be enrolled in the study. 1. Pregnant women, women who are breastfeeding or who believe they may wish to become pregnant during the course of the study. 2. Co-infection with HCV, HIV 3. Evidence of hepatocellular carcinoma (e.g. a-fetoprotein> 50 ng/mL or as evidenced by recent ultrasound or other standard of care measure) 4. Malignancy within 5 years prior to screening, with the exception of specific cancers that are cured by surgical resection (basal cell skin cancer, etc). Subjects under evaluation for possible malignancy are not eligible 5. Current alcohol or substance abuse judged by the investigator to potentially interfere with subject compliance 6. Currently receiving therapy with cytotoxic agent, nephrotoxic agents, or agents capable of modifying renal excretion 7. Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with dosing requirements. |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | The Catholic University of Korea, Daejeon St.Mary's Hosptial | Junggu | Daejeon |
Lead Sponsor | Collaborator |
---|---|
Myeong Jun Song | Chungnam National University Hospital, Gilead Sciences, Konyang University Hospital, Soonchunhyang University Hospital, Wonkwang University |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The proportion of subjects with plasma HBV DNA levels below 116 copies/mL at Week 48 | proportion of subjects with plasma HBV DNA levels below 116 copies/mL at Week 48 | week 48 | |
Primary | The proportion of subjects with plasma HBV DNA levels below 116 copies/mL at Week 96 | proportion of subjects with plasma HBV DNA levels below 116 copies/mL at Week 96 | Week 96 | |
Secondary | The proportion of subjects with plasma HBV DNA levels below 116 copies/mL at every visits | The proportion of subjects with plasma HBV DNA levels below 116 copies/mL at every visits | week 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144 | |
Secondary | The proportion of the biochemical (alanine aminotransferase normalization) response of TDF for the treatment of chronic hepatitis B at Week 48 and 96 | The proportion of the biochemical (alanine aminotransferase normalization) response of TDF for the treatment of chronic hepatitis B at Week 48 and 96 | Week 48 and 96 | |
Secondary | The proportion of the serological response (loss of HBeAg and seroconversion to HBeAb) of TDF for the treatment of chronic hepatitis B at Week 48 and 96 | The proportion of the serological response (loss of HBeAg and seroconversion to HBeAb) of TDF for the treatment of chronic hepatitis B at Week 48 and 96 | Week 48 and 96 | |
Secondary | The proportion of the serological response (loss of HBsAg and seroconversion to HBsAb) of TDF for the treatment of chronic hepatitis B at Week 48 and 96 | The proportion of the serological response (loss of HBsAg and seroconversion to HBsAb) of TDF for the treatment of chronic hepatitis B at Week 48 and 96 | Week 48 and 96 | |
Secondary | The change from baseline in the decline of HBV DNA at every visits | The change from baseline in the decline of HBV DNA at every visits | week 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144 | |
Secondary | The proportion of patients showing virological breakthrough at week 48 and 96 | The proportion of patients showing virological breakthrough at week 48 and 96. Virological Breakthrough defined as any increase in serum HBV DNA by >1 log10 from nadir or redetection of serum HBV DNA at levels =10-fold the lower limit of detection of the HBV DNA assay after having an undetectable result |
Week 48 and 96 | |
Secondary | The incidence of resistance of TDF among patients showing virological breakthrough at week 48 and 96 | The incidence of resistance of TDF among patients showing virological breakthrough at week 48 and 96. Virological Breakthrough defined as any increase in serum HBV DNA by >1 log10 from nadir or redetection of serum HBV DNA at levels =10-fold the lower limit of detection of the HBV DNA assay after having an undetectable result |
Week 48 and 96 | |
Secondary | The proportion of improvement of liver function including Child Score, Model for End-stage Liver Disease (MELD) score at Week 48 and 96 | The proportion of improvement of liver function including Child Score, MELD score at Week 48 and 96 | Week 48 and 96 | |
Secondary | The proportion of improvement of Fibrosis marker including Aspartate aminotransferase to Platelet Ratio Index(APRI) at Week 48 and 96 | The proportion of improvement of Fibrosis marker including Aspartate aminotransferase to Platelet Ratio Index(APRI) at Week 48 and 96 | Week 48 and 96 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04496882 -
Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue
|
Phase 4 | |
Completed |
NCT04083716 -
A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults
|
Phase 1 | |
Not yet recruiting |
NCT03038802 -
A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection
|
Phase 1/Phase 2 | |
Completed |
NCT05310487 -
Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects
|
Phase 1 | |
Recruiting |
NCT06070051 -
Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy
|
Phase 1 | |
Terminated |
NCT05001022 -
A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects
|
Phase 1 | |
Recruiting |
NCT04139850 -
The Establishment of Korean Hepatitis B Patients Cohort
|
||
Recruiting |
NCT05343481 -
Efficacy of VTP-300 in Chronic Hepatitis B Infection
|
Phase 2 | |
Not yet recruiting |
NCT05490836 -
Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients
|
N/A | |
Recruiting |
NCT04543565 -
Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study
|
Phase 3 | |
Active, not recruiting |
NCT02894918 -
A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAs
|
Phase 4 | |
Not yet recruiting |
NCT02793791 -
Prophylactic Treatment of Hepatic Dysplastic Nodules in HBsAg Positive Patients
|
N/A | |
Recruiting |
NCT02287857 -
Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B
|
N/A | |
Recruiting |
NCT01965418 -
A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial
|
Phase 4 | |
Recruiting |
NCT01491295 -
Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients
|
Phase 4 | |
Terminated |
NCT01872988 -
Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma
|
Phase 3 | |
Recruiting |
NCT01487876 -
Efficacy and Safety of Dual-plasmid Hepatitis B Virus DNA Vaccine in Chronic Hepatitis B Patients
|
Phase 2 | |
Completed |
NCT01531166 -
A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon
|
N/A | |
Not yet recruiting |
NCT01436539 -
Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients
|
Phase 4 | |
Recruiting |
NCT01360879 -
Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease
|
N/A |